Dx&Vx

Innovate UK award to OVM for clinical development of OVM-200

Oxford Vacmedix receives an Investor Partnership award from Innovate UK for the clinical development of lead cancer vaccine OVM-200. Oxford, UK _ 9 January 2025 Press Release – Innovate UK Award 09-Jan-25 Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, confirmed today the grant of a prestigious Investor Partnership award from Innovate UK for the clinical development of its lead cancer vaccine OVM-200. The award is made as part of the SME Round 6 p...
Read More

Oxford Vacmedix announces lead investment for Series B fund

Lead investment of $3.0 million in Oxford Vacmedix Series B from existing investors. Oxford, UK – 6th November 2024 Press Release – Oxford Vacmedix announces lead investment for Series B fund Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today the lead investment in its Series B fund of $3.0m from existing investors, Dx&Vx of Seoul, South Korea and Mr. Jin of Jia He Hui Investment of Beijing, China. Dx&Vx is OVM’s larges...
Read More
en_GBEnglish